ADC Therapeutics SA Total Liabilities 2019-2022 | ADCT

ADC Therapeutics SA total liabilities from 2019 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
ADC Therapeutics SA Annual Total Liabilities
(Millions of US $)
2021 $452
2020 $178
2019 $27
2018 $24
ADC Therapeutics SA Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $419
2021-12-31 $452
2021-09-30 $451
2021-06-30 $220
2021-03-31 $164
2020-12-31 $178
2020-09-30 $145
2020-06-30 $178
2020-03-31 $0
2019-12-31
2019-09-30 $0
2019-06-30 $0
2018-12-31 $24
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00